Clinicopathologic factors and nuclear morphometry as independent prognosticators in KIT-positive gastrointestinal stromal tumors

Journal of Histochemistry and Cytochemistry

Volumn 56, Issue 2, 2008, Pages 139-145

  Steigen, Sonja E ^a,b   Straume, Bjørn ^a   Turbin, Dmitry ^b   Chan, Andy K W ^b   Leung, Samuel ^b   Nielsen, Torsten O ^b   Lindal, Sigurd ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Gastrointestinal stromal tumor; Morphometry; Roundness

Indexed keywords

STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MORPHOMETRICS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CELL NUCLEUS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MITOSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 38649110149     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.7A7333.2007     Document Type: Article

References (24)

1. Ausems EW, van der Kamp JK, Baak JP (1985) Nuclear morphometry in the determination of the prognosis of marked atypical endometrial hyperplasia. Int J Gynecol Pathol 4:180-185
2. Baak JP, Ørbo A, van Diest PJ, Jiwa M, de Bruin P, Broeckaert M, Snijders W, et al. (2001) Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 25:930-935
3. Carrillo R, Candia A, Rodriguez-Peralto JL, Caz V (1997) Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 28:160-165
4. Cunningham RE, Federspiel BH, McCarthy WF, Sobin LH, O'Leary TJ (1993) Predicting prognosis of gastrointestinal smooth muscle tumors. Role of clinical and histologic evaluation, flow cytometry, and image cytometry. Am J Surg Pathol 17:588-594
5. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, Kordek R, Miettinen M (2001) Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 128:24-30
6. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58
7. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
8. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ (1999) Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 23:82-87
9. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, et al. (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459-465
10. Hoque A, Lippman SM, Boiko TV, Atkinson EN, Sneige N, Sahin A, Weber DM, et al. (2001) Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 10:249-259
11. Hornick JL, Fletcher CD (2007) The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 38:679-687
12. Iesalnieks I, Rummele P, Dietmaier W, Jantsch T, Zulke C, Schlitt HJ, Hofstadter F, et al. (2005) Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am J Clin Pathol 124:740-748
13. Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1-12
14. Miettinen M, Makhlouf H, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30:477-489
15. Miettinen M, Sarlomo-Rikala M, Lasota J (1998) Gastrointestinal stromal tumours. Ann Chir Gynaecol 87:278-281
16. Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term followup. Am J Surg Pathol 29:52-68
17. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sablinska K, et al. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103:821-829
18. Ozdamar SO, Bektas S, Ozdamar SE, Gedikoglu G, Gun BD, Bahadir B (2007) Nuclear morphometric analysis in gastrointestinal stromal tumors: a preliminary study. Turk J Gastroenterol 18:71-76
19. Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Akbari M, Gilks CB (2002) Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117:723-728
20. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS (1989) A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol 142:1254-1258
21. Steigen SE, Eide TJ (2006) Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS 114:192-200
22. Tan PH, Goh BB, Chiang G, Bay BH (2001) Correlation of nuclear morphometry with pathologic parameters in ductal carcinoma in situ of the breast. Mod Pathol 14:937-941
23. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG (2005) Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117:289-293
24. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato DP, Dimitrijevic S, Martens M, et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421-1423